Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose CD20 mAb for Preemptive Treatment of EBV-PTLD After Allo-HSCT
NCT05258136Unknown
- Sponsor
- Beijing Friendship Hospital
- Start
- Jun 2021
- Primary completion
- Jun 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label, single-arm trial of rituximab in lymphoproliferative disorders (LPD), sponsored by Beijing Friendship Hospital. Primary endpoints: EBV-DNA viral load at 4 weeks and Incidence of Post-Transplant Lymphoproliferative Disease at 1 year. Status: unknown.
02
Drugs
rituximab
03
Conditions
lymphoproliferative disorders (LPD)
Beyond the preview
Go deeper on NCT05258136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05258136.